The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_001204.7(BMPR2):c.247+2del

CA645294002

425732 (ClinVar)

Gene: BMPR2 (HGNC:659)
Condition: pulmonary arterial hypertension (MONDO:0015924)
Inheritance Mode: Autosomal dominant inheritance
UUID: d38b386c-73a2-4970-b3e4-063f9fa11106
Approved on: 2026-05-07
Published on: 2026-05-07

HGVS expressions

NM_001204.7:c.247+2del
NM_001204.7(BMPR2):c.247+2del
NC_000002.12:g.202464981del
CM000664.2:g.202464981del
NC_000002.11:g.203329704del
CM000664.1:g.203329704del
NC_000002.10:g.203037949del
NG_009363.1:g.93655del
ENST00000374580.10:c.247+2del
ENST00000638587.1:c.174del
ENST00000374574.2:c.247+2del
ENST00000374580.8:c.247+2del
ENST00000479069.1:n.154+2del
NM_001204.6:c.247+2del
More

Likely Pathogenic

Met criteria codes 3
PS1_Supporting PM2_Supporting PVS1_Strong
Not Met criteria codes 1
PS4

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Pulmonary Hypertension Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for BMPR2 Version 2.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Pulmonary Hypertension VCEP
The BMPR2 c. 247+2del variant is in the canonical donor site of intron 2, leading to in frame exon skipping. The variant is absent from gnomAD v4.1.0 and v2.1.1 (controls) (PM2_supporting). This variant has been reported in one heritable PAH proband (PMID:26387786) (PS4 not met). The in frame deletion removes 5.5% of the protein, including part of the critical ligand binding domain (PVS1_strong). RNA data showed two transcripts, one deleting amino acids 47-82 and one deleting aa63-82, both removing critical cysteine residues (Cys60 and Cys66) (PMID:26387786). SpliceAI (0.95) is consistent with a detrimental effect on splicing. Another variant in the same splice region, c.247+1, was classified as likely pathogenic by the PH VCEP (PS1_supporting). PP1, PS2, and PM6 were not assessed due to absence of co-segregation data. In summary, this variant meets the criteria to be classified as likely pathogenic for pulmonary arterial hypertension based on the ACMG/AMP criteria applied, as specified by the ClinGen Pulmonary Hypertension VCEP: PVS1_strong(RNA), PS1_supporting, PM2_supporting (VCEP specification version 2.0, 1/30/2026)
Met criteria codes
PS1_Supporting
Another variant in the same splice region, c.247+1, was classified as likely pathogenic by the PH VCEP.
PM2_Supporting
The variant is absent from gnomAD v2.1.1 controls and v4.1.
PVS1_Strong
Exon skipping preserves the reading frame but removes 5.5% of the protein, including part of the extracellular ligand binding domain (PVS1_strong). RNA data show two transcripts, one deleting amino acids 47-82 and one deleting aa63-82, both removing critical cysteine residues (Cys60 and Cys66). SpliceAI (0.95) is consistent with a detrimental effect on splicing.
Not Met criteria codes
PS4
The variant has been reported in one heritable PAH proband (PMID:26387786).
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
ClinGen Terms of Use.
¤ Powered by BCM's Genboree.